Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 594, 28-29 (2021)
doi: https://doi.org/10.1038/d41586-021-01267-6
Updates & Corrections
-
Correction 21 May 2021: One of the authors (B.A.S.) has added further information to their statement on competing financial interests.
References
Otten, E. G. et al. Nature 594, 111–116 (2021).
Perrin, A. J., Jiang, X., Birmingham, C. L., So, N. S. & Brumell, J. H. R. Curr. Biol. 14, 806–811 (2004).
van Wijk, S. J. L. et al. Nature Microbiol. 2, 17066 (2017).
Noad, J. et al. Nature Microbiol. 2, 17063 (2017).
Herhaus, L. & Dikic, I. Int. J. Med. Microbiol. 308, 176–184 (2018).
Huang, J. & Brumell, J. H. Nature Rev. Microbiol. 12, 101–114 (2014).
Fiskin, E., Bionda, T., Dikic, I. & Behrends, C. Mol. Cell 62, 967–981 (2016).
Ahel, J. et al. eLife 9, e56185 (2020).
Liu, W. et al. PLoS ONE 6, e22542 (2011).
Piccolis, M. et al. Mol. Cell 74, 32–44 (2019).
Banh, R. S. et al. Nature Cell Biol. 18, 803–813 (2016).
Wenzel, D. M., Lissounov, A., Brzovic, P. S. & Klevit, R. E. Nature 474, 105–108 (2011).
Competing Interests
The authors are founding scientific advisory board members of Interline Therapeutics. J.W.H. is a founder and member of the scientific advisory board of Caraway Therapeutics. B.A.S. is also on the scientific advisory board of BioTheryX and is a co-inventor of intellectual property related to DCN1 small-molecule inhibitors, licensed to Cinsano.